IP Library Granted Patent US 11,154,552
Granted Patent B2
US 11,154,552 · App. 16/904,246 · Granted Oct 26, 2021

Aripiprazole prodrug composition

Inventors: Philip Cresswell (Athlone, IE); Magali Hickey (Westwood, MA); Kristopher Perkin (Athlone, IE); Greg Smith (Norton, MA); Elaine Liversidge (Charlestown, MA); Brian Steinberg (Arlington, MA); David Manser (Keenagh, IE); Tarek Zeidan (Waltham, MA)
Assignee: ALKERMES PHARMA IRELAND LIMITED
A61K31/496A61K9/0019A61K45/06A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,154,552
App. No.
16/904,246
Granted
Oct 26, 2021
Kind
B2
Abstract

Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.

Claims (20)

1. A composition comprising:

(a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of between about 350 nm and about 175 nm as determined by light scattering techniques,

(b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug,

wherein the ratio of aripiprazole prodrug to surface stabilizer is between about 14:1 and about 22:1, and wherein the aripiprazole prodrug has the formula:

and

wherein the at least one surface stabilizer is polysorbate 20.

2. A composition comprising polysorbate 20, a chelating agent, a tonicity agent, an aqueous buffer, and a population of particles of the formula:

having a volume based particle distribution size (Dv50) between about 350 nm and about 175 nm as determined by light scattering techniques, wherein the ratio of said particles to polysorbate 20 is about 14:1 to about 22:1.

3. A composition comprising polysorbate 20, a chelating agent, a tonicity agent, an aqueous buffer, and a population of particles of the formula:

having a volume based particle distribution size (Dv50) less than about 350 nm as determined by light scattering techniques, wherein the ratio of said particles to polysorbate 20 is about 14:1 to about 22:1.

4. A composition comprising polysorbate 20 and a population of particles of the formula:

having a volume based particle distribution size (Dv50) less than about 350 nm as determined by light scattering techniques, wherein the ratio of said particles to polysorbate 20 is about 14:1 to about 22:1.

5. The composition of claim 1 , wherein the ratio of said particles to polysorbate 20 is about 17:1 to about 20:1.

6. The composition of claim 1 , wherein the ratio of said particles to polysorbate 20 is about 17:1.

7. The composition of claim 2 , wherein the ratio of said particles to polysorbate 20 is about 17:1 to about 20:1.

8. The composition of claim 2 , wherein the ratio of said particles to polysorbate 20 is about 17:1.

9. The composition of claim 3 , wherein the ratio of said particles to polysorbate 20 is about 17:1 to about 20:1.

10. The composition of claim 3 , wherein the ratio of said particles to polysorbate 20 is about 17:1.

11. The composition of claim 4 , wherein the ratio of said particles to polysorbate 20 is about 17:1 to about 20:1.

12. The composition of claim 4 , wherein the ratio of said particles to polysorbate 20 is about 17:1.

Assignments (6)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
RELEASE OF PATENT SECURITY AGREEMENTS Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0701 →
SECURITY AGREEMENT Recorded Jul 17, 2023
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 064286/0821 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2021
From: CRESSWELL, PHILIP; HICKEY, MAGALI; PERKIN, KRISTOPHER; SMITH, GREG; LIVERSIDGE, ELAINE; STEINBERG, BRIAN; MANSER, DAVID; ZEIDAN, TAREK
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 057557/0449 →